相关实验视频
Updated: Jul 28, 2025

07:25
Transdermal Measurement of Glomerular Filtration Rate in Mice
Published on: October 21, 2018
22.0K
蒂尔泽帕提德与胰岛素格拉吉因对囊素C基功能的影响:SURPASS-4后期分析
Hiddo J L Heerspink1,2, Naveed Sattar3, Imre Pavo4
1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Diabetes care
|June 2, 2023
概括
蒂尔泽帕提德通过减缓2型糖尿病成年人估计的球过率 (eGFR) 降低而显示出脏保护作用. 这种益处在基于肌素和基于囊素C的eGFR测量中都得到了一致的观察.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知蒂尔泽帕提德可以降低HbA1c和体重.
- 估计的淋巴细胞过率 (eGFR) 降低是2型糖尿病患者的一个担忧.
- 基于肌素的eGFR (eGFR-肌素) 可以受到肌肉质量的影响,与基于囊素C的eGFR (eGFR-囊素C) 不同.
研究的目的:
- 评估蒂尔泽帕提德对eGFR - 肌素和eGFR - 囊素C的影响.
- 评估特泽帕提德在高风险人群中的脏保护潜力.
主要方法:
- SURPASS-4试验包括患有2型糖尿病和高心血管风险的成年人.
- 主要结局是52周的eGFR与基线的变化.
- 提尔泽帕提德 (组合5,10,15毫克) 与标位胰岛素格拉吉因进行了比较.
主要成果:
- 与胰岛素格拉金相比,提尔泽帕提德的EGFR-肌素下降幅度较小 (-2.5毫升/分钟/1.73米2),而胰岛素格拉金的下降幅度则较小 (-3.9毫升/分钟/1.73米2).
- 蒂尔泽帕提德还显示,eGFR-cystatin C (-3,5 mL/min/1.73 m2) 与胰岛素格拉 (-5,3 mL/min/1.73 m2) 的降低较小.
- 在eGFR的变化与体重变化没有相关性.
结论:
- 蒂尔泽帕提德有效地减缓了eGFR下降的速度.
- 这些发现支持蒂尔泽帕提德对脏的保护作用.
- 药物对eGFR的影响是一致的,无论测量方法 (肌素或囊素C).
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Factors Affecting Renal Clearance: Renal Impairment
125
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
125
Serum Studies: Renal Function Tests
25
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
25
Nephrotic Syndrome II : Assessment and Medical Management
10
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
10
Chronic Kidney Disease III: Interprofessional Care
51
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
51

